Medincell
French biotech based near Montpellier, specialised in long-acting injectable formulations through its BEPO® platform. FY 2025-26 marks the acceleration of the transition toward a stable royalty model: UZEDY® (Teva, schizophrenia) generated $215M in net sales (+52.5% YoY), and olanzapine LAI (TEV-‘749) is expected to launch in the United States in Q4 2026.
Investment thesis
- 01
Patented BEPO® platform, validated through regulatory approvals (UZEDY®, in progress for olanzapine LAI) — a durable and repeatable competitive moat.
- 02
Asset-light model: commercialisation outsourced to industrial partners (Teva, AbbVie); Medincell captures the upside through royalties and milestone payments without sales force commitment.
- 03
UZEDY® (risperidone LAI, schizophrenia) accelerating commercially: $215M of Teva net sales in FY 2025-26 vs $141M in the prior year (+52.5%); associated Medincell royalties of €9.3M now structurally anchor the P&L.
- 04
Olanzapine LAI (TEV-‘749, built on Medincell's proprietary SteadyTeq™ technology) approaching market launch: FDA NDA accepted on 20 February 2026, EMA MAA accepted on 21 May 2026, US launch targeted Q4 2026 by Teva — milestones of $4M (US) and $3M (EU) on approval, mid-to-high single-digit royalties on net sales.
- 05
AbbVie partnership: the first co-developed programme is progressing toward the initiation of clinical development, broadening the portfolio beyond psychiatry.
- 06
Long-acting ivermectin programme: a non-exclusive license has been granted to the Medicines Patent Pool for low- and middle-income countries — a differentiated public-health angle.
- 07
Balance sheet reinforced in March 2026 by a €48.2M raise from US and European healthcare investors; total liquidity €84.8M (including €62.8M cash) at year-end, securing the window through the ramp-up of combined UZEDY® + olanzapine LAI royalties.
Catalysts
US launch of olanzapine LAI (TEV-‘749) by Teva
FDA approval then market launch expected in Q4 2026 per Teva's stated timeline; $4M US approval milestone, start of mid-to-high single-digit royalty flow.
EMA review of olanzapine LAI (MAA accepted 21 May 2026)
With the MAA accepted, the second key market is open; the next expected milestone is the European decision, triggering the $3M milestone and additional royalties on EU sales.
UZEDY® royalty trajectory
Quarterly read of prescription ramp-up ($215M Teva net sales on the closing year; +52.5% YoY): a direct gauge of Teva execution quality and risperidone market penetration.
First AbbVie programme entering clinical development
Expected start of the first clinical trial co-developed with AbbVie — first visible milestone of the partnership beyond the deal signing.
New partnerships / platform extensions
Medincell's ability to sign new reformulation deals: a key signal of the industry's perceived value for BEPO® after the dual UZEDY® + olanzapine LAI validation.
Annual general meeting
Scheduled for 30 September 2026; a moment of dialogue with management on royalty-transition execution, capital allocation after the €48.2M raise, and partnership strategy.
Risks
Short-term revenue concentration
At this stage, recurring revenue rests almost entirely on UZEDY® through Teva. The arrival of olanzapine LAI royalties will reduce this concentration from late 2026, but diversification remains to be confirmed.
Dependence on partner commercial choices
Medincell does not directly control pricing, reimbursement or sales force decisions. The royalty trajectory depends on Teva execution (UZEDY®, soon olanzapine LAI), then AbbVie on the first clinical programme.
FDA / EMA regulatory risk on olanzapine LAI
US NDA acceptance (February 2026) and EMA MAA acceptance (May 2026) do not guarantee final approvals; a delay or a complete-response letter from either authority would push back the US royalty start (targeted Q4 2026) or the subsequent EU decision.
Income statement still loss-making
Operating loss of €(20.8)M on the closing year for €24.3M of revenue and €45M of Opex (+17% YoY). The path to profitability depends on the dual UZEDY® + olanzapine LAI engine; the March 2026 raise (€48.2M) secures the horizon but further dilution remains possible if the trajectory slips.
Valuation multiple volatility
The market oscillates between a pharma-services / royalties reading and a biotech / pipeline reading, with significant multiple gaps. The ongoing narrative transition may amplify share-price moves.
Calendar
- 21 mai 2026Olanzapine LAI MAA accepted by EMA — review ongoingClinical
- Q4 2026Targeted FDA approval + US launch of olanzapine LAICorporate
- 30 sept. 2026Annual general meetingAGM
- 8 déc. 2026H1 FY 2026-27 resultsEarnings
- 2026-2027Partner pipeline milestones (AbbVie, Teva)Clinical
Governance
Stable historical leadership around the co-founders. Capital open to an international institutional shareholder base reinforced in March 2026 by a €48.2M capital increase from US and European healthcare investors. Solid retail shareholder community, especially active at AGMs. CapCordia documents resolutions, votes and management communications, with particular attention to the execution of the transition to the royalty model.
This file is editorial and does not constitute investment advice. Individual shareholders are responsible for their own decisions.